Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Massachusetts

www.umass.edu

Latest From University of Massachusetts

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

Deals StartUps and SMEs

Tech Transfer Roundup: J&J Innovation’s Agnostic Approach To Academic Collaboration

J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.

Deals StartUps and SMEs
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register